Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
NPS-1034 inhibits AXL and MET, including mutant forms of MET, as well as other kinases, which potentially results in decreased tumor cell growth and may overcome MET or AXL mediated drug resistance (PMID: 24173966, PMID: 24165158).
|DrugClasses||AXL Inhibitor 29 MET Inhibitor 53|
|CAS Registry Number||1221713-92-3|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Erlotinib + NPS-1034||Erlotinib NPS-1034||0||0|
|Gefitinib + NPS-1034||Gefitinib NPS-1034||0||0|